Press Releases

Mar 25

Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

CAMBRIDGE, Mass. , March 25, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Carl Morris , Ph.D., Chief Scientific Officer, will participate in a panel

Read More
Mar 23

Solid Biosciences Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

CAMBRIDGE, Mass., March 23, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. , (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the closing of its previously announced underwritten public offering of

Read More
Mar 18

Solid Biosciences Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass. , March 18, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. , (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it has priced an underwritten public offering of 21,739,131 shares of its

Read More
Mar 17

Solid Biosciences Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. , (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it has commenced an underwritten public offering of $85 million of shares

Read More
Mar 15

Solid Biosciences Reports Efficacy and Safety Data from the Ongoing IGNITE DMD Clinical Trial and Resumption of Patient Dosing in the 2E14 vg/kg Cohort

- Interim data from six patients provide evidence of a potential benefit of SGT-001 in functional endpoints of North Star Ambulatory Assessments (NSAA), 6-minute walk test (6MWT), pulmonary function tests (PFTs), and clinically validated patient reported outcome measures (PROMs) - - Patient 7,

Read More
Mar 04

Solid Biosciences Reports Inducement Grant to New Chief Legal Officer

CAMBRIDGE, Mass. , March 04, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to its newly appointed Chief Legal Officer,

Read More
Mar 04

Solid Biosciences Announces Appointments to Management Team and Board of Directors

-Adding senior level experience to help advance programs for Duchenne muscular dystrophy- CAMBRIDGE, Mass. , March 04, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne),

Read More
Feb 24

Efficacy and Safety Data from Solid Biosciences’ Ongoing IGNITE DMD Phase I/II Clinical Trial to be Presented at the 2021 MDA Clinical & Scientific Conference

- IGNITE DMD Principal Investigator, Dr. Barry Byrne , to present efficacy and safety data from the ongoing IGNITE DMD trial on Thursday, March 18 - -Company to host external key opinion leaders at a symposium to discuss Real World Outcomes Measures in Duchenne Muscular Dystrophy during the

Read More
Feb 17

Solid Biosciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider , PhD, Chief Technology Officer, and Cathryn Clary , MD, MBA,

Read More
Jan 06

Solid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. , Jan. 06, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot , Chief Executive Officer, President and Co-Founder, will present

Read More

News & Events

Press Releases